Pharma News

The study found Restoring testosterone in older men to normal level through gels, patches, or injections may lower their risk of heart attack, stroke, or death from any cause. The study appeared online in the European Heart Journal
Rajat Barua, assistant professor of medicine at the University of Kansas in the US, said, "It is the first study to demonstrate that significant benefit is observed only if the dose is adequate to normalize the total testosterone levels. Patients who failed to achieve the therapeutic range after testosterone replacement therapy did not see a reduction in (heart attack) or stroke and had significantly less benefit on mortality."

way to keep sedentary workers active at work, and improving their health. The researchers found that workers who pedaled more were more likely to report weight loss, improved concentration while at work, and fewer sick days than co-workers who pedaled less. The study appeared in the American Journal of Preventive Medicine.

Currently nasal spray flu vaccine that uses a live but weakened form of the virus is not recommended for those under two as it is thought to be too strong to be safe for kids, and too weak to be effective for the elderly. Johns Hopkins researchers have developed a method to modify the nasal spray flu vaccine to make it effective for those under two and above 49 - two groups for which the vaccine is not approved. The study published online in the journal Vaccine.

Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced an exclusive channel collaboration (ECC) to pursue the development and commercialisation of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder.

BTG plc, an international specialist healthcare company bringing announces that Health Canada has issued a Notice of Compliance approving Varithena (polidocanol injectable foam) for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system, above and below the knee.

New research has found that drug used for treatment of liver disease can also be used in treating Parkinson disease. The findings were detailed in the journal Neurology.

The US Food and Drug Administration (FDA) has approved Aprecia Pharmaceuticals Company's Spritam (levetiracetam) for oral use as a prescription adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures and primary generalised tonic-clonic seizures in adults and children with epilepsy.